Jane E Visvader

List of Publications by Year
in descending order

113 papers	22,983 citations	25034 57 h-index	20961 115 g-index
119 all docs	119 docs citations	119 times ranked	27485 citing authors

#	Article	IF	Citations
1	<i>In vivo</i> genomeâ€editing screen identifies tumor suppressor genes that cooperate with <i>Trp53</i> loss during mammary tumorigenesis. Molecular Oncology, 2022, 16, 1119-1131.	4.6	6
2	R code and downstream analysis objects for the scRNA-seq atlas of normal and tumorigenic human breast tissue. Scientific Data, 2022, 9, 96.	5.3	4
3	Intravital microscopy of dynamic single-cell behavior in mouse mammary tissue. Nature Protocols, 2021, 16, 1907-1935.	12.0	28
4	Inhibitor of Differentiation 4 (ID4) represses mammary myoepithelial differentiation via inhibition of HEB. IScience, 2021, 24, 102072.	4.1	6
5	Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids. Nature Protocols, 2021, 16, 1936-1965.	12.0	97
6	The Cellular Organization of the Mammary Gland: Insights From Microscopy. Journal of Mammary Gland Biology and Neoplasia, 2021, 26, 71-85.	2.7	16
7	A singleâ€cell RNA expression atlas of normal, preneoplastic and tumorigenic states in the human breast. EMBO Journal, 2021, 40, e107333.	7.8	170
8	Single cell transcriptome atlas of mouse mammary epithelial cells across development. Breast Cancer Research, 2021, 23, 69.	5.0	26
9	An EMTâ€"primary ciliumâ€"GLIS2 signaling axis regulates mammogenesis and claudin-low breast tumorigenesis. Science Advances, 2021, 7, eabf6063.	10.3	14
10	Mammary tumour cells remodel the bone marrow vascular microenvironment to support metastasis. Nature Communications, 2021, 12, 6920.	12.8	32
11	Stem Cells and the Differentiation Hierarchy in Mammary Gland Development. Physiological Reviews, 2020, 100, 489-523.	28.8	144
12	Modeling Breast Cancer Using CRISPR-Cas9â€"Mediated Engineering of Human Breast Organoids. Journal of the National Cancer Institute, 2020, 112, 540-544.	6.3	104
13	Targeting triple-negative breast cancers with the Smac-mimetic birinapant. Cell Death and Differentiation, 2020, 27, 2768-2780.	11.2	31
14	Tissue-resident ductal macrophages survey the mammary epithelium and facilitate tissue remodelling. Nature Cell Biology, 2020, 22, 546-558.	10.3	118
15	Halting triple negative breast cancer by targeting PROCR. Cell Research, 2019, 29, 875-876.	12.0	2
16	Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer. Nature Communications, 2019, 10, 397.	12.8	59
17	High-resolution 3D imaging of fixed and cleared organoids. Nature Protocols, 2019, 14, 1756-1771.	12.0	317
18	Intraclonal Plasticity in Mammary Tumors Revealed through Large-Scale Single-Cell Resolution 3D Imaging. Cancer Cell, 2019, 35, 618-632.e6.	16.8	119

#	ARTICLE	IF	CITATIONS
19	Isolation and Propagation of Mammary Epithelial Stem and Progenitor Cells. Methods in Molecular Biology, 2019, 1940, 217-229.	0.9	2
20	Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer. Nature Communications, 2019, 10, 766.	12.8	99
21	Foxp1 Is Indispensable for Ductal Morphogenesis and Controls the Exit of Mammary Stem Cells from Quiescence. Developmental Cell, 2018, 47, 629-644.e8.	7.0	24
22	Canonical PRC2 function is essential for mammary gland development and affects chromatin compaction in mammary organoids. PLoS Biology, 2018, 16, e2004986.	5.6	10
23	Derivation of a robust mouse mammary organoid system for studying tissue dynamics. Development (Cambridge), 2017, 144, 1065-1071.	2.5	78
24	Out-RANKing BRCA1 in Mutation Carriers. Cancer Research, 2017, 77, 595-600.	0.9	33
25	Identification of quiescent and spatially restricted mammary stem cells that are hormone responsive. Nature Cell Biology, 2017, 19, 164-176.	10.3	99
26	RE: Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2017, 109, .	6.3	11
27	Combined immune checkpoint blockade as a therapeutic strategy for <i>BRCA1</i> -mutated breast cancer. Science Translational Medicine, 2017, 9, .	12.4	227
28	Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer. Science Translational Medicine, 2017, 9, .	12.4	148
29	Construction of developmental lineage relationships in the mouse mammary gland by single-cell RNA profiling. Nature Communications, 2017, 8, 1627.	12.8	151
30	Differential methylation analysis of reduced representation bisulfite sequencing experiments using edgeR. F1000Research, 2017, 6, 2055.	1.6	70
31	Differential methylation analysis of reduced representation bisulfite sequencing experiments using edgeR. F1000Research, 2017, 6, 2055.	1.6	52
32	Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer and Metastasis Reviews, 2016, 35, 547-573.	5.9	189
33	Dysregulation of histone methyltransferases in breast cancer â€“ Opportunities for new targeted therapies?. Molecular Oncology, 2016, 10, 1497-1515.	4.6	56
34	The complexities and caveats of lineage tracing in the mammary gland. Breast Cancer Research, 2016, 18, 116.	5.0	25
35	Essential role for a novel population of binucleated mammary epithelial cells in lactation. Nature Communications, 2016, 7, 11400.	12.8	80
36	RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nature Medicine, 2016, 22, 933-939.	30.7	224

#	Article	IF	Citations
37	RUNX2 Mediates Plasmacytoid Dendritic Cell Egress from the Bone Marrow and Controls Viral Immunity. Cell Reports, 2016, 15, 866-878.	6.4	50
38	Persistent Activation of NF-Î°B in BRCA1-Deficient Mammary Progenitors Drives Aberrant Proliferation and Accumulation of DNA Damage. Cell Stem Cell, 2016, 19, 52-65.	11.1	85
39	Tissue-specific designs of stem cell hierarchies. Nature Cell Biology, 2016, 18, 349-355.	10.3	126
40	Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer. Oncogene, 2016, 35, 1877-1887.	5.9	116
41	Patient-derived xenograft models of breast cancer and their predictive power. Breast Cancer Research, 2015, 17, 17.	5.0	225
42	Recruitment and activation of SLK at the leading edge of migrating cells requires Src family kinase activity and the LIM-only protein 4. Biochimica Et Biophysica Acta - Molecular Cell Research, 2015, 1853, 1683-1692.	4.1	9
43	A pooled shRNA screen for regulators of primary mammary stem and progenitor cells identifies roles for Asap1 and Prox1. BMC Cancer, 2015, 15, 221.	2.6	31
44	EGF-mediated induction of Mcl-1 at the switch to lactation is essential for alveolar cell survival. Nature Cell Biology, 2015, 17, 365-375.	10.3	65
45	Cellular Mechanisms Underlying Intertumoral Heterogeneity. Trends in Cancer, 2015, 1, 15-23.	7.4	36
46	Integration of microRNA signatures of distinct mammary epithelial cell types with their gene expression and epigenetic portraits. Breast Cancer Research, 2015, 17, 85.	5.0	29
47	Pro-apoptotic Bim suppresses breast tumor cell metastasis and is a target gene of SNAI2. Oncogene, 2015, 34, 3926-3934.	5.9	27
48	Scribble Modulates the MAPK/Fra1 Pathway to Disrupt Luminal and Ductal Integrity and Suppress Tumour Formation in the Mammary Gland. PLoS Genetics, 2014, 10, e1004323.	3.5	54
49	Dual roles for Id4 in the regulation of estrogen signaling in the mammary gland and ovary. Development (Cambridge), 2014, 141, 3159-3164.	2.5	30
50	In situ identification of bipotent stem cells in the mammary gland. Nature, 2014, 506, 322-327.	27.8	440
51	The Mammary Stem Cell Hierarchy. Current Topics in Developmental Biology, 2014, 107, 133-160.	2.2	49
52	Mammary stem cells and the differentiation hierarchy: current status and perspectives. Genes and Development, 2014, 28, 1143-1158.	5.9	459
53	Structural Basis of the Interaction of the Breast Cancer Oncogene LMO4 with the Tumour Suppressor CtIP/RBBP8. Journal of Molecular Biology, 2013, 425, 1101-1110.	4.2	11
54	Global Changes in the Mammary Epigenome Are Induced by Hormonal Cues and Coordinated by Ezh2. Cell Reports, 2013, 3, 411-426.	6.4	117

#	Article	IF	Citations
55	Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer. Cancer Cell, 2013, 24, 120-129.	16.8	243
56	Sensitization of BCL-2â€“expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2766-2771.	7.1	173
57	Isolation of Mouse Mammary Epithelial Subpopulations: A Comparison of Leading Methods. Journal of Mammary Gland Biology and Neoplasia, 2012, 17, 91-97.	2.7	65
58	Cancer Stem Cells: Current Status and Evolving Complexities. Cell Stem Cell, 2012, 10, 717-728.	11.1	1,128
59	Aldehyde Dehydrogenase Activity Is a Biomarker of Primitive Normal Human Mammary Luminal Cells. Stem Cells, 2012, 30, 344-348.	3.2	70
60	Jekyll or Hyde: does Matrigel provide a more or less physiological environment in mammary repopulating assays?. Breast Cancer Research, 2011, 13, 108.	5.0	50
61	Mammary stem cells and their regulation by steroid hormones. Expert Review of Endocrinology and Metabolism, 2011, 6, 371-381.	2.4	3
62	Analysis of Brca1-deficient mouse mammary glands reveals reciprocal regulation of Brca1 and c-kit. Oncogene, 2011, 30, 1597-1607.	5.9	26
63	Cells of origin in cancer. Nature, 2011, 469, 314-322.	27.8	1,266
64	Hereditary Breast Cancer Geneticsâ€”From Clinical Curiosities to Mainstream Paradigms. Journal of Mammary Gland Biology and Neoplasia, 2011, 16, 1-2.	2.7	6
65	Proteomic profiling of secretome and adherent plasma membranes from distinct mammary epithelial cell subpopulations. Proteomics, 2011, 11, 4029-4039.	2.2	25
66	Lineage Specific Methylation of the <i>Elf5</i> Promoter in Mammary Epithelial Cells. Stem Cells, 2011, 29, 1611-1619.	3.2	39
67	Gata-3 Negatively Regulates the Tumor-Initiating Capacity of Mammary Luminal Progenitor Cells and Targets the Putative Tumor Suppressor Caspase-14. Molecular and Cellular Biology, 2011, 31, 4609-4622.	2.3	96
68	Aberrant expression of LMO4 induces centrosome amplification and mitotic spindle abnormalities in breast cancer cells. Journal of Pathology, 2010, 222, 271-281.	4.5	19
69	Insights into the cell of origin in breast cancer and breast cancer stem cells. Asia-Pacific Journal of Clinical Oncology, 2010, 6, 89-97.	1.1	51
70	Control of mammary stem cell function by steroid hormone signalling. Nature, 2010, 465, 798-802.	27.8	617
71	ROAST: rotation gene set tests for complex microarray experiments. Bioinformatics, 2010, 26, 2176-2182.	4.1	463
72	FOXA1 is an essential determinant of ERÎ± expression and mammary ductal morphogenesis. Development (Cambridge), 2010, 137, 2045-2054.	2.5	184

#	Article	IF	Citations
73	Stem cells and cancer â€" The promise and puzzles. Molecular Oncology, 2010, 4, 369-372.	4.6	25
74	Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Research, 2010, 12, R21.	5.0	354
75	Discovery of novel mechanosensitive genes in vivo using mouse carotid artery endothelium exposed to disturbed flow. Blood, 2010, 116, e66-e73.	1.4	136
76	Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes and Development, 2009, 23, 2563-2577.	5.9	491
77	Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nature Medicine, 2009, 15, 907-913.	30.7	1,261
78	EpCAM and solid tumour fractionation. Nature Reviews Cancer, 2009, 9, 143-143.	28.4	5
79	Resident macrophages influence stem cell activity in the mammary gland. Breast Cancer Research, 2009, 11, R62.	5.0	103
80	Deaf-1 regulates epithelial cell proliferation and side-branching in the mammary gland. BMC Developmental Biology, 2008, 8, 94.	2.1	28
81	Expression of LMO4 and outcome in pancreatic ductal adenocarcinoma. British Journal of Cancer, 2008, 98, 537-541.	6.4	23
82	Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature Reviews Cancer, 2008, 8, 755-768.	28.4	3,070
83	Notch Signaling Regulates Mammary Stem Cell Function and Luminal Cell-Fate Commitment. Cell Stem Cell, 2008, 3, 429-441.	11.1	398
84	The Mammary Progenitor Marker CD61/Î²3 Integrin Identifies Cancer Stem Cells in Mouse Models of Mammary Tumorigenesis. Cancer Research, 2008, 68, 7711-7717.	0.9	304
85	The Ets transcription factor Elf5 specifies mammary alveolar cell fate. Genes and Development, 2008, 22, 581-586.	5.9	205
86	Delineating the Epithelial Hierarchy in the Mouse Mammary Gland. Cold Spring Harbor Symposia on Quantitative Biology, 2008, 73, 469-478.	1.1	40
87	Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nature Cell Biology, 2007, 9, 201-209.	10.3	717
88	The Molecular Culprits Underlying Precocious Mammary Gland Involution. Journal of Mammary Gland Biology and Neoplasia, 2007, 12, 15-23.	2.7	30
89	The Emerging Picture of the Mouse Mammary Stem Cell. Stem Cell Reviews and Reports, 2007, 3, 114-123.	5.6	36
90	Mammary Stem Cells and Mammopoiesis: Figure 1.. Cancer Research, 2006, 66, 9798-9801.	0.9	69

#	Article	IF	Citations
91	Generation of a functional mammary gland from a single stem cell. Nature, 2006, 439, 84-88.	27.8	1,824
92	c-myc as a mediator of accelerated apoptosis and involution in mammary glands lacking Socs3. EMBO Journal, 2006, 25, 5805-5815.	7.8	48
93	Steroid Hormone Receptor Status of Mouse Mammary Stem Cells. Journal of the National Cancer Institute, 2006, 98, 1011-1014.	6.3	271
94	Elf5 is essential for early embryogenesis and mammary gland development during pregnancy and lactation. EMBO Journal, 2005, 24, 635-644.	7.8	129
95	Loss of the LIM domain protein Lmo4 in the mammary gland during pregnancy impedes lobuloalveolar development. Oncogene, 2005, 24, 4820-4828.	5.9	25
96	The LIM Domain Protein Lmo4 Is Highly Expressed in Proliferating Mouse Epithelial Tissues. Journal of Histochemistry and Cytochemistry, 2005, 53, 475-486.	2.5	39
97	Overexpression of LMO4 induces mammary hyperplasia, promotes cell invasion, and is a predictor of poor outcome in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 7659-7664.	7.1	83
98	Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer. Breast Cancer Research, 2005, 7, R1005-16.	5.0	44
99	Defective Neural Tube Closure and Anteroposterior Patterning in Mice Lacking the LIM Protein LMO4 or Its Interacting Partner Deaf-1. Molecular and Cellular Biology, 2004, 24, 2074-2082.	2.3	104
100	Tandem LIM domains provide synergistic binding in the LMO4:Ldb1 complex. EMBO Journal, 2004, 23, 3589-3598.	7.8	84
101	Structural basis for the recognition of ldb1 by the N-terminal LIM domains of LMO2 and LMO4. EMBO Journal, 2003, 22, 2224-2233.	7.8	62
102	Identification of Taxreb107 as a lactogenic hormone responsive gene in mammary epithelial cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2003, 1642, 139-147.	4.1	1
103	Mutational analysis of theLMO4 gene, encoding a BRCA1-interacting protein, in breast carcinomas. International Journal of Cancer, 2003, 107, 155-158.	5.1	13
104	LIMâ€domainâ€binding protein 1: a multifunctional cofactor that interacts with diverse proteins. EMBO Reports, 2003, 4, 1132-1137.	4.5	146
105	Two promoters within the human LMO4 gene contribute to its overexpression in breast cancer cells. Genomics, 2003, 82, 280-287.	2.9	13
106	Transcriptional regulators in mammary gland development and cancer. International Journal of Biochemistry and Cell Biology, 2003, 35, 1034-1051.	2.8	46
107	The LIM Domain Protein LMO4 Interacts with the Cofactor CtIP and the Tumor Suppressor BRCA1 and Inhibits BRCA1 Activity. Journal of Biological Chemistry, 2002, 277, 7849-7856.	3.4	135
108	CPAP Is a Novel Stat5-Interacting Cofactor that Augments Stat5-Mediated Transcriptional Activity. Molecular Endocrinology, 2002, 16, 2019-2033.	3.7	48

#	Article	IF	Citations
109	Letter to the Editor: (1)H, (15)N and (13)C assignments of FLIN4, an intramolecular LMO4:ldb1 complex. Journal of Biomolecular NMR, 2002, 23, 165-166.	2.8	4
110	The LIM domain gene LMO4 inhibits differentiation of mammary epithelial cells in vitro and is overexpressed in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 14452-14457.	7.1	124
111	The LIM-domain binding protein Ldb1 and its partner LMO2 act as negative regulators of erythroid differentiation. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 13707-13712.	7.1	141
112	The C-terminal zinc finger of GATA-1 or GATA-2 is sufficient to induce megakaryocytic differentiation of an early myeloid cell line. Molecular and Cellular Biology, 1995, 15, 634-641.	2.3	149
113	GATA-1 but not SCL induces megakaryocytic differentiation in an early myeloid line. EMBO Journal, 1992, 11, 4557-64.	7.8	59